Corifact was studied in an acute toxicity study in mice and rats at doses up to 3550 units per kg and 1420 units per kg, respectively. Repeat dose toxicity was studied in rats at daily doses up to 350 units per kg for a period of 14 days. No signs of toxicity were observed in the single dose and repeat dose studies.
A local tolerance study in rabbits demonstrated no clinical or histopathological changes at the injection site after intravenous, intra-arterial or para-venous administration of Corifact.
A thrombogenicity test was performed in rabbits at doses up to 350 units per kg. Corifact showed no thrombogenic potential at the doses tested.
Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade FDA Label. For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key coagulation factor is essential for management and prevention of bleeding episodes.
Also known as Fibrin Stabilizing Factor (FSF), Factor XIII is an endogenously produced coagulation factor and the final enzyme within the blood coagulation cascade. Within the body, FXIII circulates as a heterotetramer composed of 2 A-subunits and 2 B-subunits (A2B2)A32363. When activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. As a result, the active transglutaminase from subunit A cross-links fibrin and other proteins resulting in increased mechanical strength and resistance to fibrinolysis of the fibrin clot. This contributes to enhanced platelet and clot adhesion to injured tissue, thereby improving blood coagulation and maintenance of hemostasis A18581.
Other drug products with similar structure and function to Factor XIII (human) include DB09310, which is a recombinant form of the A subunit of human coagulation factor XIII. Compared to Factor XIII (human), which is purified from pooled human plasma, DB09310 is produced through recombinant DNA technology where the target protein is grown in yeast and then isolated FDA Label.
Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency FDA Label. As the half-life of endogenous Factor XIII is long (5-11 days), prophylactic therapy with the replacement of FXIII can be given every 4-6 to maintain hemostasisA32363.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aminocaproic acid | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Factor XIII (human). |
| Alpha-1-proteinase inhibitor | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor XIII (human). |
| Menadione | Menadione may increase the thrombogenic activities of Factor XIII (human). |
| Tranexamic acid | Tranexamic acid may increase the thrombogenic activities of Factor XIII (human). |
| Aprotinin | Aprotinin may increase the thrombogenic activities of Factor XIII (human). |
| Hydrogen peroxide | Hydrogen peroxide may increase the thrombogenic activities of Factor XIII (human). |
| Aminomethylbenzoic acid | Aminomethylbenzoic acid may increase the thrombogenic activities of Factor XIII (human). |
| Camostat | Camostat may increase the thrombogenic activities of Factor XIII (human). |
| Menadione bisulfite | Menadione bisulfite may increase the thrombogenic activities of Factor XIII (human). |
| Monteplase | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Monteplase. |
| Lepirudin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Lepirudin. |
| Bivalirudin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Bivalirudin. |
| Alteplase | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Alteplase. |
| Urokinase | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Urokinase. |
| Reteplase | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Reteplase. |
| Anistreplase | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Anistreplase. |
| Tenecteplase | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Tenecteplase. |
| Abciximab | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Abciximab. |
| Drotrecogin alfa | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Drotrecogin alfa. |
| Streptokinase | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Streptokinase. |
| Dicoumarol | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dicoumarol. |
| Argatroban | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Argatroban. |
| Ardeparin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ardeparin. |
| Phenindione | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Phenindione. |
| Fondaparinux | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Fondaparinux. |
| Warfarin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Warfarin. |
| Pentosan polysulfate | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Pentosan polysulfate. |
| Phenprocoumon | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Phenprocoumon. |
| Dipyridamole | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dipyridamole. |
| Heparin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Heparin. |
| Enoxaparin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Enoxaparin. |
| Epoprostenol | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Epoprostenol. |
| Acenocoumarol | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Acenocoumarol. |
| 4-hydroxycoumarin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with 4-hydroxycoumarin. |
| Coumarin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Coumarin. |
| Ximelagatran | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ximelagatran. |
| Desmoteplase | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Desmoteplase. |
| Defibrotide | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Defibrotide. |
| Ancrod | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ancrod. |
| Beraprost | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Beraprost. |
| Prasugrel | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Prasugrel. |
| Rivaroxaban | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Rivaroxaban. |
| Sulodexide | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Sulodexide. |
| Idraparinux | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Idraparinux. |
| Cangrelor | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Cangrelor. |
| Astaxanthin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Astaxanthin. |
| Apixaban | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Apixaban. |
| Otamixaban | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Otamixaban. |
| Amediplase | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Amediplase. |
| Dabigatran etexilate | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dabigatran etexilate. |
| Danaparoid | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Danaparoid. |
| Dalteparin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dalteparin. |
| Tinzaparin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Tinzaparin. |
| (R)-warfarin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with (R)-warfarin. |
| Ethyl biscoumacetate | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ethyl biscoumacetate. |
| Nadroparin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Nadroparin. |
| Triflusal | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Triflusal. |
| Ticagrelor | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ticagrelor. |
| Ditazole | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ditazole. |
| Vorapaxar | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Vorapaxar. |
| Edoxaban | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Edoxaban. |
| Sodium citrate | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Sodium citrate. |
| Dextran | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dextran. |
| Bemiparin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Bemiparin. |
| Parnaparin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Parnaparin. |
| Desirudin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Desirudin. |
| Antithrombin Alfa | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Antithrombin Alfa. |
| Protein C | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Protein C. |
| Antithrombin III human | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Antithrombin III human. |
| Letaxaban | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Letaxaban. |
| Darexaban | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Darexaban. |
| Betrixaban | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Betrixaban. |
| Nafamostat | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Nafamostat. |
| Gabexate | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Gabexate. |
| Fluindione | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Fluindione. |
| Protein S human | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Protein S human. |
| Brinase | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Brinase. |
| Clorindione | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Clorindione. |
| Diphenadione | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Diphenadione. |
| Tioclomarol | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Tioclomarol. |
| Melagatran | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Melagatran. |
| Saruplase | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Saruplase. |
| (S)-Warfarin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with (S)-Warfarin. |
| Tocopherylquinone | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Tocopherylquinone. |
| Dabigatran | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dabigatran. |
| Semuloparin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Semuloparin. |
| Troxerutin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Troxerutin. |
| Edetic acid | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Edetic acid. |
| Reviparin | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Reviparin. |
| Dermatan sulfate | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dermatan sulfate. |
| SR-123781A | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with SR-123781A. |
| Limaprost | The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Limaprost. |